![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
. | ![]() |
. |
![]() by Staff Writers Madrid, Spain (SPX) Mar 29, 2017
Since the ancient times, mankind has used plants to treat diseases. An example is the plant Artemisia annua, used for over 2,000 years in traditional Chinese medicine to treat intermittent fevers. Nowadays, the artemisinin molecule - the active ingredient synthesized in the microscopic hairs (trichomes) of this plant - is the main component of malaria treatments worldwide. In fact, the Chinese scientist Youyou Tu was awarded in 2015 with the Nobel Prize in Medicine for the discovery of artemisinin and its application in therapies against malaria. Regardless of artemisinin's effectiveness against malaria and other diseases caused by parasites and despite its anti-tumour potential, its usage faces a problem: the low content produced by the plant and the high cost of its chemical synthesis result in a scarce and expensive drug. Now, an international research team led by researchers from the Centre for Research in Agricultural Genomics (CRAG) and Sequentia Biotech S.L. has been able to obtain, through genetic engineering, Artemisia annua plants that produce twice as much artemisinin. The work, published in The Plant Journal, identifies a gene involved in the formation of plant trichomes and in the synthesis of terpenes, such as artemisinin. "We have discovered that the AaMYB1 gene has a dual function: it promotes trichome formation in the leaves and artemisinin synthesis inside the trichomes", explains Soraya Pelaz, ICREA researcher at CRAG and senior author of the article. "By manipulating this gene, we have managed to grow plants which contain much more artemisinin than their wild-type counterparts," she adds. Noting that 90% of malaria cases and 92% of deaths caused by this disease occur in sub-Saharan Africa, this finding could be a major step towards reducing the production costs of such a necessary drug.
The plant as a factory For the past two years, and thanks to a Torres Quevedo contract, Luis Matias-Hernandez has been directing a line of research aimed at obtaining Artemisia plants that produce large amounts of artemisinin at the spin-out Sequentia Biotech, from which he keeps collaborating with CRAG. "One of the main goals of Sequentia Biotech is to produce artemisinin of the same quality but at a lower cost. Our ambition is to reduce the price of the drug, so it can be accessible to everyone in the future", underlines Luis Matias-Hernandez. "We want to use Artemisia as a natural low-cost factory for antimalarials, and we are testing different strategies to do it," adds the researcher.
Beyond artemisinin But the investigation went further. To confirm the role of the AaMYB1 gene in the formation of plant trichomes, the researchers searched for similar genes in the model plant Arabidopsis thaliana and found the gene AtMYB61. When this gene was overexpressed in the model plant, it also produced a higher amount of trichomes on its leaves, demonstrating that these genes play a key role in the formation of trichomes in evolutionarily distant species. Soraya Pelaz explains that "in addition to its role in Artemisia, the identification of this gene can also be useful for other plants whose trichomes produce substances of interest". Luis Matias-Hernandez adds "There are many plants that produce substances of interest in their trichomes. For example, menthol and thymol are terpenes produced in the trichomes of mint and thyme, respectively."
![]() Washington (UPI) Mar 28, 2017 In order to image one of the world's largest viruses, the Samba virus, scientists at Michigan State had to design and build their own microscope. Researchers retrofitted a transmission electron microscope with a cryostage, a device used to keep biological samples frozen in liquid nitrogen. Scientists used the cryo-electron microscope to map the Samba virus and observe it as the virus in ... read more Related Links Centre for Research in Agricultural Genomics Epidemics on Earth - Bird Flu, HIV/AIDS, Ebola
![]()
![]() |
|
The content herein, unless otherwise known to be public domain, are Copyright 1995-2024 - Space Media Network. All websites are published in Australia and are solely subject to Australian law and governed by Fair Use principals for news reporting and research purposes. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA news reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. All articles labeled "by Staff Writers" include reports supplied to Space Media Network by industry news wires, PR agencies, corporate press officers and the like. Such articles are individually curated and edited by Space Media Network staff on the basis of the report's information value to our industry and professional readership. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. General Data Protection Regulation (GDPR) Statement Our advertisers use various cookies and the like to deliver the best ad banner available at one time. All network advertising suppliers have GDPR policies (Legitimate Interest) that conform with EU regulations for data collection. By using our websites you consent to cookie based advertising. If you do not agree with this then you must stop using the websites from May 25, 2018. Privacy Statement. Additional information can be found here at About Us. |